A Phase 3 interventional study of VNZ/TEZ/D-IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Enrolling by invitation at 37 sites in 10 countries. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated — 3 open to participants now, 8 under way, 5 of them phase 3. Cystic Fibrosis · Vertex Pharmaceuticals Incorporated.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 28th largest by planned enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2023, is one of 62 in phase 3, and was the 113th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →3 of the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated are open now, in 10 countries. Recruiting first, the newest first:
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 1 Year and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 24 · Phase 3 62 · Phase 4 2
First in 2007; this study’s year is marked. 5 started in 2023.
This study's planned enrollment of 174 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 73 across the 116 interventional studies, 79 across the 5 observational. Of the 112 that completed or were terminated, 80 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
4 of the studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) in participants with cystic fibrosis (CF).
Key Inclusion Criteria:
Parts A and B:
Part B:
-Meets at least 1 of the following criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Part A: Participants (Cohort 1: 6 through 11 years of age (inclusive); Cohort 2: 2 through 5 years of age (inclusive) and Cohort 3: 1 to less than (\<) 2 years of age) will receive VNZ/TEZ/D-IVA once daily at doses determined based on their age and weight. The age range is based on date of informed consent in parent study. Part B: Participants in Cohort 1 who meet the eligibility criteria will receive VNZ/TEZ/D-IVA for an additional 96 weeks.
Drug: VNZ/TEZ/D-IVA
Fixed-dose combination tablets or granules for oral administration.
Also known as: VX-121/VX-661/VX-561, VX-121/VX-661/CTP-656, vanzacaftor/tezacaftor/deutivacaftor
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)
Time frame: From Baseline up to Week 100
Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)
Time frame: From Baseline up to Week 196
Part A (All Cohorts): Absolute Change in Sweat Chloride (SwCl)
Time frame: From Baseline Through Week 96
Part B: Absolute Change in Sweat Chloride (SwCl)
Time frame: From Baseline Through Week 192
Part A (Cohort 1): Absolute Change in Percent Predicted Forced Expiratory Volume (ppFEV1)
Time frame: From Baseline Through Week 100
Part B: Absolute Change in Percent Predicted Forced Expiratory Volume (ppFEV1)
Time frame: From Baseline Through Week 196
Part A (All Cohorts): Number of Pulmonary Exacerbation (PEx)
Time frame: From Baseline Through Week 100
Part B: Number of Pulmonary Exacerbation (PEx)
Time frame: From Baseline Through Week 196
Part A (All Cohorts): Number of CF- Related Hospitalizations
Time frame: From Baseline Through Week 100
Part B: Number of CF- Related Hospitalizations
Time frame: From Baseline Through Week 196
Part A (Cohort 1): Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score
Time frame: From Baseline Through Week 100
Part B: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score
Time frame: From Baseline Through Week 196
Part A (Cohorts 1 and 2): Absolute Change in Body Mass Index (BMI)
Time frame: From Baseline Through Week 100
Part B: Absolute Change in Body Mass Index (BMI)
Time frame: From Baseline Through Week 196
Part A (Cohorts 1 and 2): Absolute Change in BMI-for-age Z-score
Time frame: From Baseline Through Week 100
Part B: Absolute Change in BMI-for-age Z-score
Time frame: From Baseline Through Week 196
Part A (Cohort 3): Absolute Change in Weight-for-length
Time frame: From Baseline Through Week 100
Part B: Absolute Change in Weight-for-length
Time frame: From Baseline Through Week 196
Part A (Cohort 3): Absolute Change in Weight-for-length Z-score
Time frame: From Baseline Through Week 100
Part B: Absolute Change in Weight-for-length Z-score
Time frame: From Baseline Through Week 196
Part A (All Cohorts): Absolute Change in Weight
Time frame: From Baseline Through Week 100
Part B: Absolute Change in Weight
Time frame: From Baseline Through Week 196
Part A (All Cohorts): Change in Weight-for-age Z-score
Time frame: From Baseline Through Week 100
Part B: Change in Weight-for-age Z-score
Time frame: From Baseline Through Week 196
Part A (Cohorts 1 and 2): Absolute Change in Height
Time frame: From Baseline Through Week 100
Part B: Absolute Change in Height
Time frame: From Baseline Through Week 196
Part A (Cohorts 1 and 2): Absolute Change in Height-for-age Z-score
Time frame: From Baseline Through Week 100
Part B: Absolute Change in Height-for-age Z-score
Time frame: From Baseline Through Week 196
Part A (Cohort 3): Absolute Change in Length
Time frame: From Baseline Through Week 100
Part B: Absolute Change in Length
Time frame: From Baseline Through Week 196
Part A (Cohort 3): Absolute Change in Length-for-age Z-score
Time frame: From Baseline Through Week 100
Part B: Absolute Change in Length-for-age Z-score
Time frame: From Baseline Through Week 196
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Jul 2029, 71 months after the start.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 71 months is above that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vertex Pharmaceuticals Incorporated →